融捷健康(300247) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 178,851,390.51, a decline of 16.87% year-on-year[7] - Net profit attributable to shareholders decreased by 30.37% to CNY 10,047,872.86 compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9,789,668.17, down 23.51% year-on-year[7] - Basic earnings per share were CNY 0.0125, a decrease of 30.17% compared to the same period last year[7] - The weighted average return on net assets was 0.63%, down from 0.04% in the previous year[7] - Total operating revenue for Q3 2019 was ¥178,851,390.51, a decrease of 17.0% compared to ¥215,155,627.19 in the same period last year[42] - Net profit for Q3 2019 was ¥8,876,137.98, compared to ¥14,285,471.47 in Q3 2018, indicating a decline of 37.0%[43] - The total comprehensive income for Q3 2019 was ¥11,070,770.83, down from ¥18,881,796.44 in Q3 2018, reflecting a decline of 41.5%[44] - The total comprehensive income for the current period is a loss of $1.84 million, compared to a gain of $5.14 million in the previous period[56] Asset and Liability Management - Total assets decreased by 8.79% to CNY 1,841,257,446.09 compared to the end of the previous year[7] - Cash and cash equivalents decreased by 60.84% compared to the beginning of the year, primarily due to the purchase of financial products and operational expenditures[18] - Accounts receivable decreased by 37.27% compared to the beginning of the year, attributed to enhanced collection efforts[18] - Total current assets decreased to CNY 749,551,152.50 from CNY 925,782,740.32, reflecting a decline of approximately 19%[33] - Total liabilities decreased to CNY 254,989,139.17 from CNY 417,448,877.28, a reduction of about 39%[34] - The company reported a net loss of CNY 610,443,795.32 as of September 30, 2019, compared to a loss of CNY 595,388,797.13 at the end of 2018[35] - The total equity attributable to shareholders decreased to CNY 1,573,409,412.74 from CNY 1,586,313,290.03, a decline of approximately 1%[35] - The company's total liabilities decreased to ¥196,443,556.81 from ¥245,897,080.21, a reduction of 20.0%[40] - The total cash and cash equivalents at the end of the period were ¥35,462,216.31, down from ¥47,992,339.27 at the end of the same quarter last year[64] Cash Flow Analysis - The company reported a net cash flow from operating activities of CNY 109,807,477.44 for the year-to-date[7] - Cash flow from operating activities generated a net amount of $109.81 million, a recovery from a negative cash flow of $56.71 million in the previous period[59] - The net cash flow from operating activities was ¥40,536,513.18, a significant improvement compared to a net outflow of ¥12,603,212.99 in the same period last year[63] - The net cash flow from financing activities was -¥47,553,512.79, an improvement from -¥65,163,179.51 year-over-year[64] Investment and R&D - Investment income increased by 42.16% year-on-year, driven by the disposal of equity in Anhui Lexin Health Management Co., Ltd. and bank financial product returns[20] - Research and development expenses for Q3 2019 were ¥8,287,673.71, a decrease of 44.0% from ¥14,774,467.47 in Q3 2018[42] - Research and development expenses for the year-to-date period were ¥29,638,334.09, a decrease from ¥35,914,963.64 in the previous year[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,070[11] - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., held 12.73% of the shares[11] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[12] Other Financial Metrics - The company experienced an asset impairment loss of ¥9,512,610.54 for the year-to-date period, compared to ¥3,007,786.68 in the previous year[51] - The company reported a financial expense of -¥3,142,786.05 for the year-to-date period, a significant decrease from -¥38,567.44 in the previous year[49] - The company reported an accumulated deficit of CNY -821,453,520.71 in undistributed profits[73]